DK0851753T3 - Aerosolpræparater - Google Patents

Aerosolpræparater

Info

Publication number
DK0851753T3
DK0851753T3 DK96931227T DK96931227T DK0851753T3 DK 0851753 T3 DK0851753 T3 DK 0851753T3 DK 96931227 T DK96931227 T DK 96931227T DK 96931227 T DK96931227 T DK 96931227T DK 0851753 T3 DK0851753 T3 DK 0851753T3
Authority
DK
Denmark
Prior art keywords
liquefied hydrofluoroalkane
fatty acid
active ingredient
medium
chain fatty
Prior art date
Application number
DK96931227T
Other languages
English (en)
Inventor
Saburo Murata
Fumio Shimojo
Yuji Tokunaga
Takehisa Hata
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of DK0851753T3 publication Critical patent/DK0851753T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK96931227T 1995-09-19 1996-09-18 Aerosolpræparater DK0851753T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23934295 1995-09-19
PCT/JP1996/002670 WO1997010806A1 (en) 1995-09-19 1996-09-18 Aerosol compositions

Publications (1)

Publication Number Publication Date
DK0851753T3 true DK0851753T3 (da) 2004-03-15

Family

ID=17043318

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96931227T DK0851753T3 (da) 1995-09-19 1996-09-18 Aerosolpræparater

Country Status (16)

Country Link
US (2) US6361760B1 (da)
EP (1) EP0851753B1 (da)
JP (2) JP3266005B2 (da)
KR (1) KR100523754B1 (da)
CN (1) CN1137680C (da)
AT (1) ATE254450T1 (da)
AU (1) AU719613B2 (da)
CA (1) CA2232378C (da)
DE (1) DE69630798T2 (da)
DK (1) DK0851753T3 (da)
ES (1) ES2206590T3 (da)
HK (1) HK1017845A1 (da)
PT (1) PT851753E (da)
TW (1) TW429153B (da)
WO (1) WO1997010806A1 (da)
ZA (1) ZA967887B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0966958A4 (en) * 1997-03-14 2001-10-10 Fujisawa Pharmaceutical Co AEROSOL PREPARATION
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
WO2003102151A2 (en) * 2002-05-30 2003-12-11 Celgene Corporation Modulating cell differentiation and treating myeloprolifertive disorders with jnk/mkk inhibitors
CA2498191C (en) 2002-09-18 2012-04-10 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
AU2002952559A0 (en) * 2002-11-08 2002-11-21 Fujisawa Pharmaceutical Co., Ltd. New use
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US20040230272A1 (en) * 2003-04-11 2004-11-18 Cates Adam W. Subcutaneous lead with temporary pharmacological agents
KR20060067922A (ko) * 2003-06-10 2006-06-20 아스텔라스세이야쿠 가부시키가이샤 마크로라이드계 화합물을 함유하는 에어로졸 조성물이봉입용기에 봉입된 에어로졸 제제
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
ZA200603719B (en) * 2003-11-06 2007-09-26 Celgene Corp Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
EP1699456A1 (en) * 2003-12-30 2006-09-13 Astellas Pharma Inc. Use of macrolides for treating or preventing airflow obstruction
MX2007006066A (es) * 2004-11-23 2007-07-11 Celgene Corp Inhibidores de jnk para el tratamiento de lesiones del snc.
US8637070B2 (en) * 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
EP2124898B1 (en) 2007-01-10 2013-08-14 Board of Regents, The University of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
EP2182980A4 (en) 2007-07-27 2012-04-18 Armagen Technologies Inc METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS
US20100098693A1 (en) * 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
KR20110096538A (ko) * 2008-11-04 2011-08-30 씨아이피엘에이 엘티디. 약제학적 에어로졸 조성물
EP2408474B1 (en) 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP3533467B1 (en) 2009-10-09 2023-07-26 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011061625A2 (en) 2009-11-19 2011-05-26 Solis Biodyne Compositions for increasing polypeptide stability and activity, and related methods
WO2011163600A2 (en) * 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
EP3024848B1 (en) 2013-07-22 2020-07-08 Armagen, Inc. Methods and compositions for increasing enzyme activity in the cns
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
ZA905202B (en) 1989-07-05 1991-04-24 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
US5215995A (en) 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
PH31204A (en) 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
IE65341B1 (en) 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
AU8910891A (en) 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
EP0669127B1 (en) 1992-11-18 1999-08-11 Fujisawa Pharmaceutical Co., Ltd. Prolonged-action pharmaceutical preparation
JPH06345646A (ja) 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US5681501A (en) * 1995-10-11 1997-10-28 E. I. Du Pont De Nemours And Company Compositions including a hydrofluoropropane
EP0966958A4 (en) * 1997-03-14 2001-10-10 Fujisawa Pharmaceutical Co AEROSOL PREPARATION
WO1998046268A1 (fr) 1997-04-11 1998-10-22 Fujisawa Pharmaceutical Co., Ltd. Composition medicamenteuse

Also Published As

Publication number Publication date
AU719613B2 (en) 2000-05-11
JP2000505050A (ja) 2000-04-25
CN1137680C (zh) 2004-02-11
CN1201384A (zh) 1998-12-09
CA2232378C (en) 2009-04-14
EP0851753B1 (en) 2003-11-19
JP3266005B2 (ja) 2002-03-18
DE69630798D1 (de) 2003-12-24
US20020061906A1 (en) 2002-05-23
HK1017845A1 (en) 1999-12-03
KR100523754B1 (ko) 2007-06-04
US6361760B1 (en) 2002-03-26
PT851753E (pt) 2004-04-30
KR19990044656A (ko) 1999-06-25
ZA967887B (en) 1997-04-07
ES2206590T3 (es) 2004-05-16
JPH09143054A (ja) 1997-06-03
WO1997010806A1 (en) 1997-03-27
DE69630798T2 (de) 2004-09-23
CA2232378A1 (en) 1997-03-27
AU6999896A (en) 1997-04-09
ATE254450T1 (de) 2003-12-15
EP0851753A1 (en) 1998-07-08
US6524556B2 (en) 2003-02-25
JP3362394B2 (ja) 2003-01-07
TW429153B (en) 2001-04-11

Similar Documents

Publication Publication Date Title
DK0851753T3 (da) Aerosolpræparater
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
GB2062465B (en) Topical preparation containing nitroglycerine and optionally other medicaments
AR021922A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol.
BR9805993A (pt) Composição farmacêutica de aerosol.
KR930007444A (ko) 4-비페닐아세트 산(bpaa)를 함유하는 제약학적 조성물
AU2001288460A1 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
MY118301A (en) Local anesthetic for external use
AR021921A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido.
CA2103060A1 (en) Penetration-Promoting Substance
FI962056A0 (fi) Uusi farmaseuttinen koostumus stabiilin jauheen valmistamiseksi, joka sisältää asetyylisalisyylihapon ja metoklopramidin yhdistelmän käsittävän aktiivisen aineosan
NZ512194A (en) A pharmaceutical composition comprising cyclosporin in a lipid carrier
EP0968713A4 (en) PATCHES CONTAINING ISOSORBID NITRATE
GR1002731B (el) Φαρμακευτικα ενεσιμα διαλυματα περιεχοντα συνδυασμους παρακεταμολης με αλλες δραστικες ουσιες.
AU8740198A (en) Inhibitor and preservative formulation
EP0966958A4 (en) AEROSOL PREPARATION
AU3080092A (en) Slow-release ibuprofen-containing medicament and its use
ES456094A1 (es) Un procedimiento para la preparacion de 2-acetoxi-benzoato de 2-(carbamoil) fenilo.
ES2085657T3 (es) Un medicamento de accion retardada que contiene flurbiprofeno y su utilizacion.
IE811773L (en) Pharmaceutical comosition containing imidazolesalicylate
JPS5762220A (en) Embrocation for external use
ES2043093T3 (es) Composicion para uso cosmetico o farmaceutico.
MX9707073A (es) Preparaciones de aerosol de prilocaina e hidrofluorocarbono.
TH35053A (th) ยาชาที่มีผลเฉพาะแห่งสำหรับใช้ภายนอก
KR900009086A (ko) 정맥확장증 치료용 조서물 및 그의 제조방법